Drugs / HIV-1 DNA vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00061243 | Apr 2004 → Apr 2005 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HIV-1 DNA vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00061243 ↗ |
| Modality | Vaccine | “The first vaccine component administered in this study is a DNA vaccination” NCT00061243 ↗ |
| Route | Intramuscular | “Groups 4 and 5 will receive the vaccine through either intradermal or intramuscular administration” NCT00061243 ↗ |